Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Sugen Incorporated

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Ben-gurion University of the Negev Research and Development Authority

Other

Rhone-poulenc Rorer Pharmaceuticals Inc.

Yissum Research Development

University of California

Hadasit Medical Research Services and Development Ltd.

Bio-signal Corporation Ltd.

Notox, Ltd.

Gazit, Aviv

Slavin, Shimon

Aviv Gazit

Alexander Levitzki

Peng Cho Tang

Klaus Peter Hirth

Elaina Mann

Axel Ullrich

Laura Kay Shawver

Alex Levitzki

Chaim Gilon

Harald App

Gerald M McMahon

Istvan Szekely

Shimon Slavin

Esther Priel

Reiner Lammers

Jianming Tsai

Janis Haimichael

Hui Chen

Tamas Bajor

Sara Yitzchak

Gershon Golomb

Birgit Millauer

Donna Pruess Schwartz

Werner Risau

Shmuel Banai

Alfred P Spada

Paul E Persons

Dennis J Slamon

Michael Chorev

Gyorgi Keri

S David Gertz

Frank D Boehmer

Johannes Waltenberger

Fairooz F Kabbinavar

Eyal Yosef Mishani

Yulia Rozen

Giuseppina Ortu

David Gertz

Laura K Shawyer

Abraham Novogrodsky

Thomas Bonasera

The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.

Telomerase activating compounds and methods of use thereof

The present invention relates to a novel class of tri-aryl compounds, compositions comprising the same and processes for the preparation thereof.

Tri-aryl compounds and compositions comprising the same

The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention s based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.

Cell line comprising vector encoding truncated FLK-1 receptor

The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity HER2 or EGFR.

Method and compositions for inhibiting cell proliferative disorders

A method of inhibiting cell proliferation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition comprising, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, which is a substituted styrene compound which can also be a naphthalene, an indane or a benzoxazine; including nitrile and molononitrile compounds, and pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of such compound.

Styryl compounds which inhibit EGF receptor protein tyrosine kinase

The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and truncated Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.

Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein

PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same

Methods and compositions for inhibiting cell proliferative disorders

Compounds useful for countering undesired toxic effects to cells, tissues or organs having formula (I) wherein: Ar is a group of formulae (i) or (ii), n is 0 or, when Ar has formula (i) above, then n may also be 1, R is CN, &mdash;GC(S)NH , &mdash;C(O)NHR or, when R is 4-NO add R is H or 3-OH, then R may also be a group of formulae (iii), (iv), (v), (vi) where R is H, phenyl, phenyl(lower alkyl) or pyridylmethyl; R and R are each independently H, OH, NO or, when R is CN, also CH , F, or CF , provided that both R and R are not simultaneously H.

Pharmaceutical compositions comprising tyrphostins

The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG.,), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Treatment of platelet derived growth factor related disorders such as cancers

A radiolabeled compound of a formula: ##STR1## is described. R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, carboxy, carbalkoxy and salts thereof; and A, B, C and D are each independently selected from the group consisting of a hydrogen and an electron withdrawing group, provided that at least one of A, B, C and D is [18]fluorine.

Epidermal growth factor receptor binding compounds for positron emission

The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Treatment of platelet derived growth factor related disorders such as

Growing community of inventors

Jerusalem, Israel

Aviv Gazit